Avoiding downstream testing ultimately makes it cheaper for whoever is footing the bill, says Merrill H. Stewart, MD, Ochsner Health.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Panelists discuss how chronic neuroinflammation involves distinct mechanisms from acute relapses—including microglial ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...

A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Panelists emphasize that effective use of menin inhibitors for KMT2A-rearranged acute myeloid leukemia (AML) requires dispelling common misconceptions about oral targeted therapy, ensuring close ...

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

The Supreme Court decision in Medina v Planned Parenthood interprets the Social Security Acts Medicaid provision as not being ...

The Braidwood decision maintains the status quo for many patients, keeping preventive services covered by Medicaid under the ...

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.